Researchers believe the vaccine could be effective against a new strain of the corona virus, says the head of AstraZeneca, a company that develops the Code 19 vaccine in collaboration with a pharmaceutical company and Oxford University.
Researchers have developed a successful formula for the development of the vaccine that will make it as effective as other vaccines, said AstraZeneca’s chief executive, Pakel Soroit, in an interview.
Some quarters have suggested that the vaccine may not be as good as the one developed by Fizer.
The results of the final trial indicated that the Oxford University vaccine was up to 70% effective in preventing code 19, while the efficacy of the Pfizer vaccine was 95%.
“We think we’ve determined a successful formula and its usefulness. I can’t say more about that yet, the results will be released,” said Pascal Suriot.
The use of the vaccine is expected to be approved by the British government next week.
According to reports, the vaccine will be introduced to the public in the UK from the first week of January.
When asked how effective the vaccine would be against a new strain of the corona virus that has spread to the UK, Pascal Soroit said: “So far we think this vaccine will be effective, but we are not sure. Will check.
British officials say the new type has led to an increase in the number of cases across the country.
He says the new strain is more contagious, but it does not increase the severity of the disease.
Several countries have imposed travel bans on the UK following the discovery of the new type, but so far this new type of case has surfaced in various countries around the world.